Exaggerated vascular and renal pathology in endothelin-B-receptor-deficient rats with subtotal nephrectomy

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Tazawa, Naoko ^a   Okada, Yuka ^a   Nakata, Mariko ^a   Izumoto, Hiromi ^a   Takasu, Mai ^a   Takaoka, Masanori ^a   Gariepy, Cheryl E ^b   Yanagisawa, Masashi ^c   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Chronic renal failure; Endothelin 1; Endothelin B receptor; Hypertension; Renal mass reduction

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN B RECEPTOR;

ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIAL BLOOD; BIOCHEMISTRY; BLOOD SAMPLING; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; GENE DELETION; GLOMERULOPATHY; HEART; HISTOPATHOLOGY; HOMOZYGOSITY; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; VASCULAR DISEASE; WILD TYPE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; AORTA; BLOOD PRESSURE; BLOOD UREA NITROGEN; CREATININE; ENDOTHELIN-1; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; NEPHRECTOMY; RATS; RECEPTOR, ENDOTHELIN B; TIME FACTORS; UP-REGULATION;

EID: 11144301283     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166316.45882.94     Document Type: Conference Paper

References (23)

1. Benigni A, Zoja C, Corna D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993;44:440-444.
2. Brochu E, Lacasse MS, Moreau C, et al. Endothelin ETA receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant. 1999;14:1881-1888.
3. Nabokov A, Amann K, Wagner J, et al. Influence of specific and non-specific endothelin receptor antagonists on renal morphology in rats with surgical renal ablation. Nephrol Dial Transplant. 1996;11: 514-520.
4. Nabokov A, Amann K, Wessels S, et al. Endothelin receptor antagonists influence cardiovascular morphology in uremic rats. Kidney Int. 1999; 55:512-519.
5. Gariepy CE, Williams SC, Cass DT, et al. Null mutasion of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci U.S.A. 1996;93: 867-872.
6. Gariepy CE, Williams SC, Richardson JA, et al. Transgenic expression of the endothelin-B receptor prevents congenital intestinal aganglionosis in rat model of Hirschsprung disease. J Clin Invest. 1998;102: 1092-1101.
7. Gariepy CE, Ohuchi T, Williams SC, et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105:925-933.
8. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br J Pharmacol. 1995;114:925-930.
9. Matsumura Y, Kuro T, Kobayashi Y, et al. Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension. Circulation. 2000;102: 2765-2773.
10. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318:1657-1666.
11. Bidani AK, Schwartz MM, Lewis EJ. Renal autoregulation and vulnerability to hypertensive injury in remnant kidney. Am J Physiol. 1987;252:F1003-F1010.
12. A receptor antagonist BQ123 antagonizes endothelin-1-mediated mitogenesis. Eur J Pharmacol. 1992;225:347-350.
13. Kohno M, Horio T, Yokokawa K, et al. Endothelin modulates the mitogenic effect of PDGF on glomerular mesangial cells. Am J Physiol. 1994;266:F894-F900.
14. Fukuda K, Yanagida T, Okuda S, et al. Role of endothelin as a mitogen in experimental glomerulonephritis in rats. Kidney Int. 1996;49: 1320-1329.
15. De Nucci G, Thomas R, D'Orlèans-Juste P, et al. The pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U.S.A. 1988;85:9797-9800.
16. Takayanagi R, Kitazumi K, Takasaki C, et al. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation. FEBS Lett. 1991;282:103-106.
17. Brooks DP, DePalma PD, Pullen M, et al. Characterization of canine renal endothelin receptor subtypes and their function. J Pharmacol Exp Ther. 1994;268:1091-1097.
18. B receptor-mediated action on systemic and renal hemodynamics and urine formation in deoxycorticosterone acetate-salt-induced hypertensive rats. Biol Pharm Bull. 1998;21:800-804.
19. Konishi F, Okada Y, Takaoka M, et al. Role of endothelin ETB receptors in the renal hemodynamic and excretory responses to big endothelin-1. Eur J Pharmacol. 2002;451:177-184.
20. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83: 1774-1777.
21. Mattana J, Singhal RP. L-Arginine supplementation antagonizes the effects of angiotensin II and endothelin-1 on mesangial cell proliferation. Cell Physiol Biochem. 1995;5:176-192.
22. Reyes AA, Purkerson ML, Karl I, et al. Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis. 1992;20:168-176.
23. Fujihara CK, De Nucci G, Zatz R. Chronic nitric oxide synthase inhibition aggravates glomerular injury in rats with subtotal nephrectomy. J Am Soc Nephrol. 1995;5:1498-1507.